Proactive research analyst John Savin speaks to Thomas Warne after publishing a research note about the latest Covid trial from development-stage antiviral company NanoViricides (NYSE-A:NNVC).
The ongoing NV-CoV-2 Phase Ia clinical study is a key milestone in the development of Nanoviricides' (NV) novel and innovative anti-virus therapy, NV-CoV-2 uses a sophisticated polymer (NV-387) as the active ingredient to trap and disrupt viruses in the blood.
The therapy aims to reduce the viral load to prevent infection of healthy cells and to enable the immune system to clear viruses rapidly.